In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 176 to 200 of 301

TitleTypeExpected publication date
NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]Technology appraisal guidanceTBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]Technology appraisal guidance
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]Technology appraisal guidance
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]Technology appraisal guidance
Omburtamab for treating relapsed neuroblastoma [ID1664]Technology appraisal guidanceTBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]Technology appraisal guidanceTBC
Orforglipron for managing overweight and obesity [ID6516]Technology appraisal guidance
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]Technology appraisal guidanceTBC
Oveporexton for treating type 1 narcolepsy [ID6622]Technology appraisal guidanceTBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Technology appraisal guidanceTBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]Technology appraisal guidance
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]Technology appraisal guidanceTBC
Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]Technology appraisal guidanceTBC
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Technology appraisal guidanceTBC
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]Technology appraisal guidanceTBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Technology appraisal guidance
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473]Technology appraisal guidanceTBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]Technology appraisal guidanceTBC
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Technology appraisal guidance
Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]Technology appraisal guidance
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All